181 related articles for article (PubMed ID: 36293565)
21. Multi-label transcriptional classification of colorectal cancer reflects tumor cell population heterogeneity.
Cascianelli S; Barbera C; Ulla AA; Grassi E; Lupo B; Pasini D; Bertotti A; Trusolino L; Medico E; Isella C; Masseroli M
Genome Med; 2023 May; 15(1):37. PubMed ID: 37189167
[TBL] [Abstract][Full Text] [Related]
22. Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases.
Ubink I; van Eden WJ; Snaebjornsson P; Kok NFM; van Kuik J; van Grevenstein WMU; Laclé MM; Sanders J; Fijneman RJA; Elias SG; Borel Rinkes IHM; Aalbers AGJ; Kranenburg O
Br J Surg; 2018 Jan; 105(2):e204-e211. PubMed ID: 29341165
[TBL] [Abstract][Full Text] [Related]
23. The prognostic significance of tumor-infiltrating lymphocytes assessment with hematoxylin and eosin sections in resected primary lung adenocarcinoma.
Kim A; Lee SJ; Ahn J; Park WY; Shin DH; Lee CH; Kwon H; Jeong YJ; Ahn HY; I H; Kim YD; Cho JS
PLoS One; 2019; 14(11):e0224430. PubMed ID: 31743333
[TBL] [Abstract][Full Text] [Related]
24. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
[TBL] [Abstract][Full Text] [Related]
25. A new method for evaluating tumor-infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (H-E)-stained tumor sections.
Iseki Y; Shibutani M; Maeda K; Nagahara H; Fukuoka T; Matsutani S; Kashiwagi S; Tanaka H; Hirakawa K; Ohira M
PLoS One; 2018; 13(4):e0192744. PubMed ID: 29698402
[TBL] [Abstract][Full Text] [Related]
26. A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier.
Shinto E; Oki E; Shimokawa M; Yamaguchi S; Ishiguro M; Morita M; Kusumoto T; Tomita N; Hashiguchi Y; Tanaka M; Ohnuma S; Tada S; Matsushima T; Hase K
Oncology; 2020; 98(8):534-541. PubMed ID: 32235113
[TBL] [Abstract][Full Text] [Related]
27. Histopathological Significance and Prognostic Impact of Tumor Budding in Colorectal Cancer.
Mehta A; Goswami M; Sinha R; Dogra A
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2447-2453. PubMed ID: 30255698
[TBL] [Abstract][Full Text] [Related]
28. Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Ten Hoorn S; de Back TR; Sommeijer DW; Vermeulen L
J Natl Cancer Inst; 2022 Apr; 114(4):503-516. PubMed ID: 34077519
[TBL] [Abstract][Full Text] [Related]
29. Tumor Budding in Colorectal Carcinoma Showing a Paradoxical Mitotic Index (Via PHH3) With Possible Association to the Tumor Stromal Microenvironment.
Hacking S; Sajjan S; Angert M; Ebare K; Jin C; Chavarria H; Kataria N; Zhang L; Cho M; Thomas R; Lee L; Nasim M
Appl Immunohistochem Mol Morphol; 2020 Sep; 28(8):627-634. PubMed ID: 31567276
[TBL] [Abstract][Full Text] [Related]
30. Peritumoral tertiary lymphoid structure and tumor stroma percentage predict the prognosis of patients with non-metastatic colorectal cancer.
Wang Q; Shen X; An R; Bai J; Dong J; Cai H; Zhu H; Zhong W; Chen W; Liu A; Du J
Front Immunol; 2022; 13():962056. PubMed ID: 36189233
[TBL] [Abstract][Full Text] [Related]
31. Postoperative circulating tumor DNA combined with consensus molecular subtypes can better predict outcomes in stage III colon cancers: A prospective cohort study.
Li Y; Mo S; Zhang L; Ma X; Hu X; Huang D; Lu B; Luo C; Peng H; Cai S; Sheng W; Peng J
Eur J Cancer; 2022 Jul; 169():198-209. PubMed ID: 35636041
[TBL] [Abstract][Full Text] [Related]
32. Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer.
Tarazona N; Gimeno-Valiente F; Gambardella V; Huerta M; Roselló S; Zuniga S; Calon A; Carbonell-Asins JA; Fontana E; Martinez-Ciarpaglini C; Eason K; Rentero-Garrido P; Fleitas T; Papaccio F; Moro-Valdezate D; Nyamundanda G; Castillo J; Espí A; Sadanandam A; Roda D; Cervantes A
ESMO Open; 2020 Sep; 5(5):e000847. PubMed ID: 32967918
[TBL] [Abstract][Full Text] [Related]
33. Whole-Slide Image Analysis Reveals Quantitative Landscape of Tumor-Immune Microenvironment in Colorectal Cancers.
Yoo SY; Park HE; Kim JH; Wen X; Jeong S; Cho NY; Gwon HG; Kim K; Lee HS; Jeong SY; Park KJ; Han SW; Kim TY; Bae JM; Kang GH
Clin Cancer Res; 2020 Feb; 26(4):870-881. PubMed ID: 31757879
[TBL] [Abstract][Full Text] [Related]
34. The potential role of platelets in the consensus molecular subtypes of colorectal cancer.
Lam M; Roszik J; Kanikarla-Marie P; Davis JS; Morris J; Kopetz S; Menter DG
Cancer Metastasis Rev; 2017 Jun; 36(2):273-288. PubMed ID: 28681242
[TBL] [Abstract][Full Text] [Related]
35. Cartilage Oligomeric Matrix Protein, COMP may be a Better Prognostic Marker Than CEACAM5 and Correlates With Colon Cancer Molecular Subtypes, Tumor Aggressiveness and Overall Survival.
Wusterbarth E; Chen Y; Jecius H; Krall E; Runyan RB; Pandey R; Nfonsam V
J Surg Res; 2022 Feb; 270():169-177. PubMed ID: 34687957
[TBL] [Abstract][Full Text] [Related]
36. A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer.
Piskol R; Huw L; Sergin I; Kljin C; Modrusan Z; Kim D; Kljavin N; Tam R; Patel R; Burton J; Penuel E; Qu X; Koeppen H; Sumiyoshi T; de Sauvage F; Lackner MR; de Sousa E Melo F; Kabbarah O
Clin Cancer Res; 2019 Jul; 25(14):4431-4442. PubMed ID: 31004000
[TBL] [Abstract][Full Text] [Related]
37. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry.
Li X; Larsson P; Ljuslinder I; Ling A; Löfgren-Burström A; Zingmark C; Edin S; Palmqvist R
Pathol Res Pract; 2021 Apr; 220():153379. PubMed ID: 33721619
[TBL] [Abstract][Full Text] [Related]
38. Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision.
Rebersek M
Radiol Oncol; 2020 May; 54(3):272-277. PubMed ID: 32463385
[TBL] [Abstract][Full Text] [Related]
39. Consensus molecular subtyping of colorectal cancers is influenced by goblet cell content.
Miller SA; Ghobashi AH; O'Hagan HM
Cancer Genet; 2021 Jun; 254-255():34-39. PubMed ID: 33571895
[TBL] [Abstract][Full Text] [Related]
40. Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy.
Allen WL; Dunne PD; McDade S; Scanlon E; Loughrey M; Coleman H; McCann C; McLaughlin K; Nemeth Z; Syed N; Jithesh P; Arthur K; Wilson R; Coyle V; McArt D; Murray GI; Samuel L; Nuciforo P; Jimenez J; Argiles G; Dienstmann R; Tabernero J; Messerini L; Nobili S; Mini E; Sheahan K; Ryan E; Johnston PG; Van Schaeybroeck S; Lawler M; Longley DB
JCO Precis Oncol; 2018 Jun; 2018():. PubMed ID: 30088816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
